Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Allison Marie Martin, M.D.
Instructor, Oncology and Pediatrics
Instructor of Oncology
Expertise: Pediatric Oncology
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital (Main Entrance)
Appointment Phone: 410-955-8751
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287 map
Dr. Allison Martin is an Instructor in Pediatric Oncology at the Johns Hopkins Children’s Center. From the outset of her medical career, she knew that she wanted to find a cure for children’s brain tumors. Her research focuses on finding new treatments for medulloblastoma, the most common children’s brain tumor. She is exploring new ways to trigger the body’s own immune defenses to block brain tumor activity, and she is breaking new ground in finding ways to stimulate immune system pathways to check cancerous tumor growth.
She first became interested in the immunity of the central nervous system when she was a medical student at Jefferson Medical College. She went on to complete a pediatric residency at the University of Pittsburgh Medical Center, and came to Johns Hopkins as a pediatric hematology/oncology fellow in 2013. She was appointed to the Johns Hopkins University Faculty in 2014.
Dr. Martin is pursuing her research in the laboratory of Drew M. Pardoll, MD, PhD, a world-renowned tumor immunologist. She is experimenting with mice to study the mechanisms of the immune system and their potential for governing cancer-causing activity in the body. These pre-clinical models will be key to our understanding of important pathways in medulloblastoma, so that treatments for children with this disease can be developed. The next phase will be to design new clinical trials aimed at actually improving the cure rate for children’s brain tumors.
- Instructor, Oncology and Pediatrics
- Instructor of Oncology
- Instructor of Pediatrics
- MD, Jefferson Medical College of Thomas Jefferson University (2007)
- Children's Hospital of Pittsburgh-UPMC / Pediatrics (2010)
- Johns Hopkins University School of Medicine / Pediatric Hematology & Oncology (2014)
- American Board of Pediatrics / Hematology/Oncology (2015)
- American Board of Pediatrics / Pediatrics (2010)
- 2010 Medical Licensure in the State of Maryland, Issued 02/22/2010; Exp: 09/15, #D70297
- 2010 Board Certified Pediatrics, Issued: 10/18/2010, Certificate No. 98107
Research & Publications
Nauen DW, Martin A, Katz A, Cohen D, Ranganathan S. A Case of Luteinizing Thecoma with Sclerosing Peritonitis: revisiting a link with anti-epileptic drugs, Pediatric Blood and Cancer 2010;54(3):470-2.
Academic Affiliations & Courses
Courses and Syllabi
2000 – 2001 Teaching Assistant, Biology 101/102 laboratory, Dept. of Biology, Bryn Mawr College, Bryn Mawr, PA
2000 - 2001
Videos & Media
Lectures and Presentations
Poster presented by Angela Alme at Johns Hopkins 7th Annual Prostate Research Day. Title: Expression of Immune Checkpoint Ligands on Prostate Cancer Cells: Implications for Adaptive Immune Escape. Authors: Christopher Nirschl, BS, Allison Martin, MD, Angela Alme, BS and Charles G. Drake, MD, PhD.
Martin A, Nirschl C, Polanczyk M, Cohen KJ, Pardoll DM, Drake CG, Lim M. Novel Immune Characteristics of Medulloblastoma Correlate with MYC Amplification Status, Neuro-Oncolog, 2012; 93[Abstract]. Presented at the15th Annual International Society of Pediatric Neuro-Oncology, Toronto, Canada. Poster#46.
Martin A, Nirschl C, Polanczyk M, Cohen KJ, Pardoll DM, Drake CG, Lim M. Oncogenic Drivers of Medulloblastoma May Determine a Novel Immune Phenotype, Neuro Oncology. 2012;14(Suppl6): 41[ Abstract]. Presented at 17th Annual Society for Neuro-Oncology, Washington, D.C.,Poster #16.
Martin A, Nirschl C, Polanczyk M, Cohen KJ, Pardoll DM, Drake CG, Lim M. MYC Amplification Status Influences Tumor Immune Evasion in Medulloblastoma, presented at the Pediatric Oncology Branch National Cancer Institute Pediatric Research Round Up.
Martin, A, Nirschl, C, Polanczyk,M, Bell, R, Martinez, D, Sullivan, LM, Santi, M, Burger, PC, Taube, JM, Drake, CG, Pardoll, DM, Lim, M. Differential expression of PD-L1 on Hematopoietic versus Tumor Cells in Medulloblastoma, To be presented at the 14th International Society of Pediatric Neuro-Oncology. Changi, Singapore. Abstracts to be published in Journal of Neuro-Oncology. Poster MB-073.
Immune Characteristics of Pediatric Brain Tumors presented at Tumor Immunology Research in Progress, Department of Cancer Immunology, Johns Hopkins University.
Oral Presentation (01/23/2012)
Presented Mortality and Morbidity Conference for the Department of Oncology, Johns Hopkins University
Oral Presentation (04/06/2012)
Presented Pediatric Trends in Hematology under supervision of John Joseph Strouse, M.D., Ph.D, The Johns Hopkins Hospital, Baltimore, MD. Selected to present two cases of thrombocytopenia to community pediatricians as part of a pediatric education day.
Oral Presentation (04/19/2012)
Presence of MYC Alters the Expression of Co-Inhibitory Receptors PD-L1 and PD-L2 in Medulloblastoma presented at Tumor Immunology Research in Progress, Department of Cancer Immunology, Johns Hopkins University
Oral Presentation (01/14/2013)
Presented Pediatric Trends in Oncology under the supervision of Allen Chen, M.D., Ph.D. The Johns Hopkins Hospital, Baltimore, MD. Selected to present a case of central line infection to community pediatricians as part of a pediatric education day.
Oral Presentation (04/15/2013)
Martin A, Nirschl C, Polanczyk M, Cohen KJ, Pardoll DM, Drake CG, Lim M. MYC Amplification Status Influences Tumor Immune Evasion in Medulloblastoma, Neuro-Oncology 2013;15(suppl 1): 15-16[Abstract]. Platform Presentation at Pediatric Neuro-Oncology Basic and Translational Research Conference, Fort Lauderdale, Florida.
Oral Presentation (05/17/2013)